Anzeige
Mehr »
Login
Sonntag, 19.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C3Y0 | ISIN: US90240B1061 | Ticker-Symbol:
NASDAQ
17.05.24
21:59 Uhr
18,240 US-Dollar
-0,860
-4,50 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TYRA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
TYRA BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur TYRA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.05.Tyra Biosciences GAAP EPS of -$0.35 beats by $0.111
09.05.Tyra Biosciences, Inc. - 10-Q, Quarterly Report1
09.05.Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights35- TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 - - Susan...
► Artikel lesen
07.05.Tyra Biosciences, Inc. - 8-K, Current Report1
07.05.Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors9CARLSBAD, Calif., May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
► Artikel lesen
20.03.HCH drug potential boosts Tyra Biosciences' stock PT at H.C. Wainwright2
20.03.Tyra Biosciences Inc reports results for the quarter ended in December - Earnings Summary2
19.03.Tyra Biosciences GAAP EPS of -$0.53 misses by $0.051
19.03.Tyra Biosciences files to sell 15.37M shares of common stock for holders1
19.03.Tyra Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
19.03.Tyra Biosciences, Inc. - 10-K, Annual Report1
19.03.Tyra Biosciences, Inc. - 8-K, Current Report1
19.03.Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights86- Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 -- TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 -- Initiated SURF201 Phase 1 study and dosed...
► Artikel lesen
02.02.Tyra Biosciences spikes on $200M private financing4
02.02.Tyra Biosciences secures $200 million in private financing1
02.02.Tyra Biosciences' TYRA-300 gains FDA rare paediatric disease status1
02.02.Tyra Bio up on FDA's rare pediatric disease tag for dwarfism therapy1
01.02.Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia196CARLSBAD, Calif., Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
► Artikel lesen
01.02.Tyra Biosciences, Inc. - 8-K, Current Report1
22.12.23Tyra Biosciences, Inc. - 8-K, Current Report1
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1